---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-011430"
form_type: "8-K"
ticker: "CYCN"
cik: "0001755237"
company_name: "Cyclerion Therapeutics, Inc."
filed_at: "2022-06-10T23:59:59+00:00"
generated_at: "2026-06-25T02:50:35.812635+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cyclerion (CYCN) reports positive topline data for CY6463 in MELAS study; improvements in biomarkers

## Summary
- Open-label, eight-patient study showed improvements in lactate, GDF-15, inflammatory biomarkers, cerebral blood flow, and functional connectivity after 29 days.
- CY6463 was well tolerated with no serious adverse events or treatment discontinuations; PK consistent with Phase 1.
- 75% of patients were on standard-of-care arginine or citrulline; effects more pronounced in patients with greater baseline disease burden.
- Data support further development of CY6463 in CNS diseases with mitochondrial dysfunction, including schizophrenia and Alzheimer's disease.

## SEC filing metadata
- accession: 0000950170-22-011430
- form_type: 8-K
- ticker: CYCN
- cik: 0001755237
- company_name: Cyclerion Therapeutics, Inc.
- filed_at: 2022-06-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1755237/000095017022011430/0000950170-22-011430-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1755237/000095017022011430/cycn-20220610.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-011430
- JSON: https://secwatch.observer/filing/0000950170-22-011430.json
- Plain text: https://secwatch.observer/filing/0000950170-22-011430.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.